1·Conclusion The plasminogen ability is lower in women with PCOS.
结论PCOS患者的血纤溶能力较正常对照者有所下降。
2·We studied the mechanism of plasma and tissue kallikrein in activating plasminogen.
作者研究了血浆和组织激肽释放酶激活纤溶酶原的机制。
3·Plasminogen activator inhibitor-1 (PAI-1) is the main regulator of the fibrinolytic system.
血浆纤溶酶原激活物抑制剂(PAI) - 1是纤溶系统的主要调控因子。
4·We measured the plasminogen (PLG) content and plasmin (pl) activity in 54 leukemic patients.
对54例白血病患者进行血浆纤溶酶原(plg)及纤溶酶(PL)活性测定。
5·Urokinase, a human plasminogen activator, is used clinically to promote the dissolution of thrombi.
尿激酶是一种纤溶酶原激活剂，临床上用于治疗血栓。
6·HMGB1 plays roles in activation of plasminogen and matrix metalloproteases, reorganization of cytoskeleton.
HMGB1与纤维蛋白酶原、基质金属蛋白酶的活化、细胞骨架重组等有关。
7·This method provided a new, fast and efficient method for large-scale purification of plasminogen for clinic use.
为规模化快速纯化临床用高纯度纤溶酶原提供了新方法。
8·NIHSS scores were determined before tissue plasminogen activator bolus and at 60 and 120 minutes in both data sets.
在两个试验中，在组织纤维蛋白溶酶原激活剂使用前，都先用NIHSS评分。
9·Plasminogen activator inhibitor-1 (PAI-1) is a single strand glycoprotein, which can inhibit plasminogen activation.
纤溶酶原激活物抑制剂1 (PAI - 1)是一种单链糖蛋白，起抑制纤溶活性的作用。
10·Conclusion The diabetic nephropathy patients have imbalance of plasma plasminogen activator and its inhibitor system.
结论：糖尿病肾病患者存在血浆纤溶酶原激活物及其抑制物系统失衡。